OptrumRx, To Keep AbbVie’s Humira 3 Others On Its Formulary In 2023
According to a Bloomberg report, OptrumRx, UnitedHealth’s pharmacy benefit manager, will keep AbbVie’s best-selling rheumatoid arthritis drug Humira on its formulary in 2023 alongside three competing biosimilar versions set to debut next year.
Heather Cianfrocco, CEO of Optum Rx, disclosed the decision at the HLTH conference held Nov. 15 in Las Vegas. OptumRx is the nation’s third largest PBM and the first to disclose how it will handle new competition for Humira.
The PBM said it will not prefer one version of the drug over another in its formulary.
Adalimumab, sold under the brand name Humira, among others, is a monoclonal antibody used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. Humira has generated nearly $200 billion in sales for AbbVie. The company’s stock rose 1.7 percent upon news of OptumRx’s decision. You can get more information on: Humira: Frequently Asked Questions (FAQs)
